Publication | Closed Access

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Hematological MalignancyCell TherapyImmunotherapyCiltacabtagene AutoleucelMedicineHematologyImmunologyPhase 1B/2Immune Checkpoint InhibitorRadiation OncologyOncologyCell TransplantationRefractory Multiple MyelomaHealth Sciences